SHARE: Report Back from SABCS Focusing on Metastatic Breast Cancer

Wednesday, April 12, 2023

1

San Antonio Breast Cancer Symposium- 2013

The Future of Metastatic Breast Cancer

Stephen C. Malamud MDMedical OncologyBeth Israel Medical Center-Comprehensive Cancer Center

Breast Cancer:Surgery for Stage IV ?


3

Tata Memorial Study

Tata Memorial (India)- 350 patients from 2005-2012 Endpoint- overall survival Projected benefit: median survival-

increase in survival from 18 to 24 months Initial therapy in experimental arm-

CAF+/- T Stratifications: number and type of

metastases, ER status, age, menopause Subset analysis: age, ER status, HER2

status, number and type of metastases


7


8


9

Study size: 271 (2008-12) Endpoint: overall survival Initial therapy: primary site local

therapy Stratification: none described Inclusion of radiotherapy: yes Subset analysis planned: age,

ER/Her2/triple negative, one organ site; bone only; all other solitary bone lesions; multiple bone lesions

Turkish Study:


11


12


13


14

Tata Memorial Study:

Turkey: both groups median age 52 Tata Memorial: 47 and 48 Turkey: tumor size- more T2 and T4 tumors in ST arm; grade

similar between 2 arms Tata Memorial: tumor size: not described; grade not

described Both studies: Lymph node involvement not described Tata Memorial: ER+: 51% and 49% Turkey- fewer ER+ and more Triple Negative patients on the

ST arm Metastatic burden: Tata- balanced for >3 lesions, Turkey-

single organ site more frequent in surgical arm Bone only metastases- Tata- balanced between arms; Turkey-

fewer in ST arm, non-bone metastases more frequent in ST arm

Study characteristics:Comparative Analysis


19


20


21


22


23


24


25


26


27


28


29


30


31


32


33


34


35


36


37


38


39


40


41


42


43


44


45

Health & Medicine

SHARE: Report Back from SABCS Focusing on Metastatic Breast Cancer